Objective: To observe the clinical effect of Gualou Xiebai Banxia decoction combined with Tanreqing injection in treating acute attack of chronic pulmonary heart disease (CPHD) and their influence on hypersensitive C-reactive protein (hs-CRP) and N-terminal brain natriuretic peptide precursor (NT-proBNP). Method: Totally 108 patients were randomly divided into the control group (53 cases) and the observation group (55 cases) according to the digital table method. The control group was treated with comprehensive western medicine therapies

including intravenous injection with cefpirome sulfate (2 g/time

qd)

oral administration with ambroxol hydrochloride granules (30 mg/time

tid) and of Salmeterol xinafoate aerosol two puffs

(2×25) μg

2 bid. Based on the therapies of the control group

the observation group was additionally treated with oral administration with Gualou Xiebai Banxia decoction (qd)

intravenous infusion with Tanreqing injection (30 mL/time

qd). Both groups were treated for 14 days. Before and after the treatment

New York Heart Association (NYHA) graded and scored main symptoms and signs

tested the forced vital capacity (FVC)

forced expiratory volume in 1 second (FEV1)

peak expiratory flow (PEF)

arterial partial pressure of oxygen (PaO2)

oxygen saturation (SaO2)

hs-CRP and NT-proBNP levels. Result: After the treatment

the total effective rate of cardiac function in the observation group was 90.91% and higher than 77.36% in the control group

but with no statistical significance in their difference. The total effective rate of comprehensive clinical efficacy in the observation group was 89.09% and higher than 69.81% in the control group (P<0.05). The levels of FVC

FEV1

PEF

PaO2 and SaO2 in both group were slightly higher than that before the treatment (P<0.01)

with higher PEF

PaO2 and SaO2 in the observation group than that in the control group (P<0.05) and no statistical significance in FVC and FEV1 between the two groups.The cough

expectoration

asthma

oppression in chest and lung rale scores in both groups where notably lower than that before the treatment (P<0.01).Except for asthma

other symptoms and sign scores in the observation group were lower than that in the control group (P<0.01).And the levels of hs-CRP and NT-proBNP in the observation group were lower than that in the control group (P<0.01). Conclusion: Based on the conventional western medicine therapies

Gualou Xiebai Banxia decoction combined with Tanreqing injection can ameliorate symptoms of phlegm

cough

dyspnea and oppression in chest and cardiac and pulmonary functions

relieve the inflammatory response and improve the comprehensive efficacy.